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Drug developmentMarked successes in treating a wide variety of malignancies in both adults and children have raised concerns
about the cardiotoxic sequelae of several mainstream and emerging cancer therapies. There is a critical need
for the health care community to more quickly and reliably identify the unique treatment-related cardiac risks
facing patients with cancer. Meeting these needs will likely involve identifying new biomarkers of early and re-
versible cardiotoxicity, designing and optimizing dosing and drug selection, and developing oncology drugs that
can be administeredwith protectant therapies to improve safety proﬁles. Non-clinical studies offer the opportu-
nity tomore thoroughly characterize underlying biologicalmechanisms thatmight aid in designing and optimiz-
ing safer drugs. The Health and Environmental Sciences Institute (HESI), a global, non-proﬁt institute that
promotes multi-sector scientiﬁc partnerships along with other academic, government, patient-advocacy, and
clinical partners, proposes to develop novel collaborations to develop newways of performing non-clinical safety
assessments that will beneﬁt patient quality of life.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Traditional approaches to non-clinical safety assessment for new
medicines are not often speciﬁc to patient phenotypes and clinical treat-
ment regimens. Nowhere is this truer than for oncology drugs, for
which poly-pharmacy is the norm, co-morbidities are common, treat-
ments can last from weeks to years, and patients can be of any age.
Marked successes in treating awide variety ofmalignancies in both adults
and children have raised concerns about the cardiotoxic sequelae of sev-
eral mainstream and emerging cancer therapies. These concerns have
prompted a unique partnership among cardiologists and oncologists
(e.g., International Cardio-Oncology Society) and related workshops
(e.g., NCI/NHLBI workshop “Cancer Treatment-Related Cardiotoxicity:
Understanding the Current State of Knowledge and Developing Future
Research Priorities,” Bethesda, MD; March 2013) to improve clinical
approaches to detecting and managing treatment-related toxicity in
patients with cancer [1,2].
Members of the Health and Environmental Sciences Institute's (HESI)
Cardiac Safety Technical Committee recently met with members of this
community in a satellite roundtable discussion after the International Col-
loquium on Cardio-Oncology in Rome, Italy. This discussion explored, Washington, DC 20005, United
land Ltd. This is an open access articleopportunities for the non-clinical cardiovascular safety community to
contribute to this partnership by improving the understanding andman-
agement of clinical cardiotoxicity resulting from cancer therapies. Specif-
ically, the attendees identiﬁed a critical need for the health care
community to more quickly and reliably identify the unique treatment-
related cardiac risks facing patients with cancer. Meeting these needs
will likely involve identifying new biomarkers of early and reversible
cardiotoxicity, designing and optimizing dosing and drug selection, and
developing oncology drugs that can be administered with protectant
therapies to improve safety proﬁles.
The Health and Environmental Sciences Institute (HESI) is a global,
non-proﬁt institute that promotesmulti-sector scientiﬁc partnerships be-
tween academic, government, clinical, non-governmental organizations,
and industry stakeholders to develop and validate new approaches to im-
prove human and environmental health. HESI's Cardiac Safety Committee
conducts research and develops best-practices through a series of work-
ing groups dedicated to improving the clinical relevance of non-clinical
cardiovascular safety assessment. The Committee has ongoing initiatives
on pro-arrhythmia prediction, biomarkers of coagulation, induced plurip-
otent stem-cell-derived cardiomyocytes as in vitro testing platforms, and
integrative approaches to drug safety assessment [3].
Non-clinical pharmaceutical safety assessment is a globally
regulated process that uses several prescribed in vitro and in vivo assays.
These assays are important in assuring safety at all pre-clinical and clinical
phases of drug development. Importantly, most standard in vivo non-under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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consisting of healthy adult animals. As such, non-clinical databases and
evidence are built on evidence from a relatively homogenous set of ani-
malmodel phenotypes. In vivo assessments of acute drug-induced chang-
es in cardiovascular function are outlined in ICH guidelines (S7a, S7b).
These assessments have translated well from animal models to clinical
use and have protected patients in Phase I clinical trials from severe and
unintended adverse effects [4,5]. Although these studies are generally
single-dose studies of instrumented animals where a range of physiologic
cardiovascular measures are possible, they tend to be biased toward a
focus on ECGmeasures of pro-arrhythmic risk as the endpoint of primary
concern because drugs that prolong the QT interval may induce fatal
arrhythmias.
Repeat-dose general toxicity studies are a mainstay for evaluating
the more chronic risks associated with new drugs and include both
morphologic (e.g. histopathologic) and biochemical endpoints (clinical
pathology assessments). Histopathologic analyses can assess drug-
induced changes in cardiac structure with much more precision than
is possible with clinical endpoints. Alternatively, cardiac troponins and
natriuretic peptides are sometimes collected in these animal studies
much like they are from patients with cardiovascular disease [6].
Measures of cardiac function in repeat-dose studies are often restricted
to non-invasive ECG measures, although the capacity is improving in
the measurement of blood pressure with non- or minimally-invasive
methods and cardiac contractility with echocardiography [7].
Standard single- or repeat-dose, pre-clinical toxicity studies in ani-
mals have for decades provided important assessments of potential
safety risks, but new approaches to preventing and monitoring long-
term health risks in particularly susceptible patients are needed. Clini-
cally relevant, non-clinical study designs are needed to explore the ef-
fect of single or combined treatments in animals with neoplasia, with
other co-morbidities, pre-treated with anthracyclines, or receiving
additional radiation therapy. New dosing strategies (bolus, repeat-,
interrupted-dose) and protective therapies need to be developed.
Clinically relevant cardiac function needs to be assessed in repeat-dose
studies that can be augmented with high-resolution morphologic
assessments (e.g., with light or electron microscopy), transcriptomic
endpoints, or even cellular biochemistry [8]. Non-clinical studies also
offer the opportunity to more thoroughly characterize underlying
biological mechanisms that might aid in designing and optimizing
safer drugs.
However, the difﬁculties designing, conducting, and funding such
studies should not be underestimated. Patient phenotypes and geno-
types are incredibly variable and not easily replicated in animal models.
Therapeutic regimens are likewise variable and are often personalized
for an individual patient or tumor type. Substantial efforts and diverse
expertise are needed to ensure that the outcomes of such studies are
robust and relevant.To achieve these challenging goals, strong partnerships among
stakeholders are needed to develop new ways of performing non-
clinical safety assessments. Stakeholders must determine how these
studies would support contemporary safety regulations. These studies
cannot draw on the considerable experience that more traditional
studies have had in differentiating speciﬁc drug-related risks. Further,
the potential for disparaging a drug with irrelevant non-clinical safety
concerns is real and may deny patients access to a truly life-saving
medicine. Risk-monitoring strategies may be difﬁcult to manage, in-
crease costs, and possibly result in false information. Third-party payers
may also be reluctant to support prospective monitoring of these risks.
Strategies that might improve patient care and increase the effec-
tiveness of new therapies need to be explored. Workshops such as the
Colloquium and those sponsored by the NCI and NHLBI have brought
key stakeholders to the discussion, identiﬁed gaps in knowledge, and
proposed actions to close these gaps. Furthering these discussions re-
quires a close partnership between clinical and non-clinical oncology
and cardiovascular experts and between regulators, academics, pa-
tients, research foundations, and drug developers. A venue and funding
must also be identiﬁed. Nevertheless, the partnership between the HESI
Cardiac Safety Committee, the cardio-oncology community, and other
stakeholders can provide the foundation for substantially improving
the safety and effectiveness of cancer treatment.
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